| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Constance Bordet, Philippe Garcia, Francesco Salvo, Anthony Touafchia, Michel Galinier, Agnès Sommet, François Montastru. Antipsychotics and risk of QT prolongation: a pharmacovigilance study. Psychopharmacology. 2022-12-14. PMID:36515735. |
while meta-analyses of clinical trials found that lurasidone and partial dopamine agonists (brexpiprazole and aripiprazole) were the antipsychotics less likely to cause qtc prolongation, and sertindole, amisulpride, and ziprasidone were the most frequently associated with this adverse drug reaction; no real-world studies have investigated this risk between the different antipsychotics. |
2022-12-14 |
2023-08-14 |
Not clear |
| David Taylor, Ramalingam Chithiramohan, Jasdev Grewal, Avirup Gupta, Lars Hansen, Gavin P Reynolds, Sofia Papp. Dopamine partial agonists: a discrete class of antipsychotics. International journal of psychiatry in clinical practice. 2022-12-10. PMID:36495086. |
worldwide, there are now three marketed dopamine d2 partial agonists: aripiprazole, brexpiprazole and cariprazine. |
2022-12-10 |
2023-08-14 |
Not clear |
| Adiba Anam, Sean Lynch, Nafiz Mosharraf, Chloe Soukas, Dmitriy Gekhma. Aripiprazole: examining the clinical implications of D2 affinity. International clinical psychopharmacology. 2022-09-27. PMID:36165513. |
aripiprazole has extremely high binding affinity for the dopamine d2 receptor, which is the receptor thought to be responsible for the antipsychotic effect, although aripiprazole is not the most potent of the second generation antipsychotics. |
2022-09-27 |
2023-08-14 |
Not clear |
| Satoko Sumi, Takahiko Nagamine, Koji Sumi, Reona Aijima, Kyoko Oka, Akira Toyofuk. Case report: Open bite as an extrapyramidal side effect with aripiprazole, a dopamine partial agonist. Frontiers in psychiatry. vol 13. 2022-09-23. PMID:36147978. |
case report: open bite as an extrapyramidal side effect with aripiprazole, a dopamine partial agonist. |
2022-09-23 |
2023-08-14 |
Not clear |
| Yusuke Matsuzaka, Manabu Noguchi, Shigeki Kanamura, Kengo Maeda, Takahiro Hisano, Daizo Tanaka, Yukihiro Ando, Tomokazu Yamamoto, Yoshiro Morimoto, Hiroki Ozawa, Toshihiro Otsuk. Combination therapy of modified electroconvulsive therapy and long-acting injectable aripiprazole for dopamine supersensitivity psychosis: a case report. Neurocase. 2022-08-22. PMID:35993136. |
combination therapy of modified electroconvulsive therapy and long-acting injectable aripiprazole for dopamine supersensitivity psychosis: a case report. |
2022-08-22 |
2023-08-14 |
Not clear |
| Jae Hyun Ryou, Doug Hyun Han, Reeree Lee, Sun Mi Ki. Aripiprazole Improved Post-Streptococcal Dyskinesia by Modulating Dopaminergic Activity: A Case Report. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 20. issue 3. 2022-07-25. PMID:35879044. |
this case report aimed to discuss the efficacy of aripiprazole for dyskinesia in patients with functional movement disorder after streptococcal infection, with its biological action of modulating dopamine hyperactivity in the basal ganglia as a dopamine partial agonist. |
2022-07-25 |
2023-08-14 |
Not clear |
| Jae Hyun Ryou, Doug Hyun Han, Reeree Lee, Sun Mi Ki. Aripiprazole Improved Post-Streptococcal Dyskinesia by Modulating Dopaminergic Activity: A Case Report. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 20. issue 3. 2022-07-25. PMID:35879044. |
this report has shown that the [18f] n -(3-fluoropropyl)-2β-carbon ethoxy-3β-(4-iodophenyl) nortropane positron emission tomography findings of the patient revealed that the dopamine hyperactivity in the basal ganglia at baseline was normalized after aripiprazole treatment due to its balancing effect as a dopamine partial agonist. |
2022-07-25 |
2023-08-14 |
Not clear |
| Seoyoung Kim, Elena Younhye Ock, Jun Soo Kwon, Euitae Ki. Relationship between subjective well-being and aripiprazole: an [ Scientific reports. vol 12. issue 1. 2022-07-15. PMID:35840763. |
relationship between subjective well-being and aripiprazole: an [ the dopamine blockade by antipsychotics trigger subjective dysphoria. |
2022-07-15 |
2023-08-14 |
Not clear |
| Dilshana Nafisa, Anil Kakunj. Aripiprazole-induced obsessive-compulsive symptoms. Industrial psychiatry journal. vol 31. issue 1. 2022-07-08. PMID:35800864. |
aripiprazole is a novel antipsychotic with a unique pharmacological profile as a dopamine partial agonist. |
2022-07-08 |
2023-08-14 |
Not clear |
| David Fraguas, David Almenta Gallego, Sergio Arques-Egea, Marcos Gómez-Revuelta, Carlos Gómez Sánchez-Lafuente, Daniel Hernández Huerta, Daniel Núñez Arias, Beatriz Oda Plasencia-García, Carlos Parro Torres, Samuel Leopoldo Romero-Guillena, Elena Ros Cucurul, Cecilio Alam. Aripiprazole for the treatment of schizophrenia: Recommendations of a panel of Spanish experts on its use in clinical practice. International journal of psychiatry in clinical practice. 2022-07-06. PMID:35792729. |
aripiprazole is an antipsychotic with a partial agonism of dopamine d |
2022-07-06 |
2023-08-14 |
Not clear |
| Mattia Ferraiolo, Romane Ponthot, Hicham Atik, Beryl Koener, Julien Hanson, Emmanuel Herman. Receptor Density Influences the Recruitment Bias of Aripiprazole and Brexpiprazole at the Dopamine D Fundamental & clinical pharmacology. 2022-06-29. PMID:35767599. |
receptor density influences the recruitment bias of aripiprazole and brexpiprazole at the dopamine d aripiprazole, brexpiprazole and cariprazine are dopamine d |
2022-06-29 |
2023-08-14 |
Not clear |
| Guillaume Meyer, Clara Gitahy Falcao Faria, Marine Beck, Marielle Riutort, Bruno Michel, Hervé Javelo. Suicidality and psychotic episodes after starting aripiprazole: two case reports. International clinical psychopharmacology. 2022-06-13. PMID:35695655. |
we agree with previous reports and recommend careful management when switching from strong dopamine antagonists to aripiprazole. |
2022-06-13 |
2023-08-14 |
Not clear |
| b' Mevludin Hasanovi\\xc4\\x87, Abdurahman Kuldija, Izet Pajevi\\xc4\\x87, Miro Jakovljevi\\xc4\\x87, Muhammed Hasanovi\\xc4\\x8. Gambling Disorder as an Addictive Disorder and Creative Psychopharmacotherapy. Psychiatria Danubina. vol 33. issue Suppl 4. 2022-03-30. PMID:35354178.' |
due to the possibility of the emergence of problem gambling and other impulse-control deficits we need to be very careful when commencing a patient on dopamine replacement therapy or therapy with aripiprazole. |
2022-03-30 |
2023-08-13 |
Not clear |
| Nobuhisa Kanahara, Hiroshi Kimura, Yasunori Oda, Fumiaki Ito, Masaomi Iy. Recent discussions on dopamine supersensitivity psychosis: Eight points to consider when diagnosing treatment-resistant schizophrenia. Current neuropharmacology. 2022-03-11. PMID:35272593. |
this review examines the data dealing with dopamine supersensitivity with the five themes of frequency, severity, withdrawal studies, switching to aripiprazole, and tardive dyskinesia. |
2022-03-11 |
2023-08-13 |
Not clear |
| Ana Jalles, Cármen Vieira, Joana Pereira-Sousa, Daniela Vilasboas-Campos, Ana Francisca Mota, Sara Vasconcelos, Bruna Ferreira-Lomba, Marta Daniela Costa, Jorge Diogo Da Silva, Patrícia Maciel, Andreia Teixeira-Castr. Aripiprazole Offsets Mutant ATXN3-Induced Motor Dysfunction by Targeting Dopamine D Biomedicines. vol 10. issue 2. 2022-02-25. PMID:35203579. |
aripiprazole offsets mutant atxn3-induced motor dysfunction by targeting dopamine d the atypical antipsychotic aripiprazole is a food and drug administration-approved drug for the treatment of psychotic, mood, and other psychiatric disorders. |
2022-02-25 |
2023-08-13 |
Not clear |
| Ana Jalles, Cármen Vieira, Joana Pereira-Sousa, Daniela Vilasboas-Campos, Ana Francisca Mota, Sara Vasconcelos, Bruna Ferreira-Lomba, Marta Daniela Costa, Jorge Diogo Da Silva, Patrícia Maciel, Andreia Teixeira-Castr. Aripiprazole Offsets Mutant ATXN3-Induced Motor Dysfunction by Targeting Dopamine D Biomedicines. vol 10. issue 2. 2022-02-25. PMID:35203579. |
dopamine partial agonism and functional selectivity have been proposed as the main pharmacological mechanism of action of aripiprazole in the treatment of psychosis; however, this mechanism remains to be determined in the context of mjd. |
2022-02-25 |
2023-08-13 |
Not clear |
| Geoffrey Russell, Samuel Reinfeld, Olivia Kam, Gloria Lee, Melissa Weiss, Maju Mathew Kool. Case series on aripiprazole and dopamine supersensitivity psychosis. International clinical psychopharmacology. 2022-02-10. PMID:35143441. |
case series on aripiprazole and dopamine supersensitivity psychosis. |
2022-02-10 |
2023-08-13 |
Not clear |
| Geoffrey Russell, Samuel Reinfeld, Olivia Kam, Gloria Lee, Melissa Weiss, Maju Mathew Kool. Case series on aripiprazole and dopamine supersensitivity psychosis. International clinical psychopharmacology. 2022-02-10. PMID:35143441. |
there have since been numerous published case reports describing this phenomenon, but only recently has the concept of a theoretical aripiprazole-induced dopamine supersensitivity psychosis (dsp) caused by d2 receptor activation in patients undergoing a switch to aripiprazole appeared in the literature. |
2022-02-10 |
2023-08-13 |
Not clear |
| Ahmed Al-Qassabi, Ahmed Al Sinan. Dopamine Dysregulation Syndrome in Parkinson Disease and Remission After Treatment With Aripiprazole. Journal of clinical psychopharmacology. 2022-02-09. PMID:35135978. |
dopamine dysregulation syndrome in parkinson disease and remission after treatment with aripiprazole. |
2022-02-09 |
2023-08-13 |
Not clear |
| Chia-Hao Ma, Hung-Yu Chan, Ming H Hsieh, Chen-Chung Liu, Chih-Min Liu, Hai-Gwo Hwu, Ching-Hua Kuo, Wei J Chen, Tzung-Jeng Hwan. Identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia. Therapeutic advances in psychopharmacology. vol 12. 2022-02-03. PMID:35111295. |
identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia. |
2022-02-03 |
2023-08-13 |
Not clear |